DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Engelman JA, Zejnullahu K, Gale CM et al.
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Cancer Res 2007;
67: 11924-11932
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.